Is this the age of the big biotech buyout? Is cold brew a business expense? And how do you pronounce “Gonzalez”?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Matt Herper joins us to break down the Senate Finance Committee hearing that saw seven pharmaceutical executives taken to task on the topic of drug pricing. Then, Matt sticks around to talk about what a spate of billion-dollar deals mean for the future of biotech. Later, STAT reporter Kate Sheridan stops by to talk about what you can — and can’t — learn about stealthy biotech startups when you do a little digging. Finally, we embark upon a lightning round that touches on Bristol-Myers Squibb’s increasingly difficult quest to buy Celgene (CELG), a controversial effort toward gender parity, and some unwanted brand recognition for Novartis (NVS).

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy